Zynerba Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ZYNE Nasdaq 8731 http://zynerba.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome - Jan 11th, 2023 1:30 pm
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth? - Jan 8th, 2023 2:56 pm
UPDATE 2-Zynerba delays genetic disorder drug data on enrollment challenge - Dec 21st, 2022 12:29 pm
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome - Dec 21st, 2022 12:00 pm
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology - Dec 5th, 2022 12:30 pm
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology - Nov 29th, 2022 12:00 pm
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders - Nov 28th, 2022 12:30 pm
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome - Nov 15th, 2022 12:30 pm
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights - Nov 14th, 2022 12:30 pm
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome - Nov 2nd, 2022 11:30 am
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit - Oct 17th, 2022 11:00 am
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit - Oct 10th, 2022 11:00 am
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ - Oct 6th, 2022 11:00 am
Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference - Sep 29th, 2022 11:00 am
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference - Sep 22nd, 2022 11:00 am
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium - Sep 8th, 2022 1:15 pm
Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference - Sep 6th, 2022 11:00 am
Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium - Aug 31st, 2022 11:00 am
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights - Aug 10th, 2022 11:00 am
Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference - Aug 3rd, 2022 11:00 am